FIG. 1.

Study design and patient disposition. ^a0.125 mg/day (patients weighing 20 kg to <45 kg). ^b0.175 mg/day (patients weighing≥45 kg). ^cPatients randomly assigned to placebo during double-blind (DB) phase who continued into open-label extension (OLE) and received risperidone. ^dPatients randomly assigned to risperidone low dose in DB phase and receiving risperidone (as per weight class) in OLE phase. ^ePatients randomly assigned to risperidone high dose in DB phase and receiving risperidone (as per weight class) in OLE phase.